Naratriptan Hcl Teva

Naratriptan, the active ingredient in Naratriptan Hcl Teva, is a Triptan (5‑HT1B/1D receptor agonist) presented as an oral tablet for oral use. It is indicated for the acute treatment of migraine attacks in adults.

GNH USA supplies Naratriptan Hcl Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Naratriptan belongs to the triptan class and is used to treat migraine attacks.

- Migraine: provides acute relief of headache pain and associated symptoms. - Migraine with aura: alleviates visual and sensory disturbances accompanying the headache. - Episodic migraine: reduces the severity and duration of individual migraine episodes.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Dizziness: transient light‑headedness. - Fatigue: feeling unusually tired. - Dry mouth: reduced salivation. - Tingling: paresthesia in extremities. - Drowsiness: increased sleepiness.

Serious or Rare Side Effects: - Chest pain: possible cardiac ischemia. - Severe hypertension: sudden rise in blood pressure. - Serotonin syndrome: agitation, hyperthermia, tremor. - Allergic reaction: rash, swelling, difficulty breathing. - Arrhythmia: irregular heart rhythm. - Ischemic events: stroke or myocardial infarction.

Before using Naratriptan, consider the following precautions.

- Cardiovascular disease: assess risk of coronary artery disease before treatment. - Hepatic impairment: use with caution in patients with liver dysfunction. - Concomitant serotonergic agents: avoid combinations that may trigger serotonin syndrome. - Pregnancy: limited safety data; prescribe only if benefits outweigh risks. - Breastfeeding: unknown excretion in milk; evaluate necessity. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Naratriptan may interact with several medicines.

Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertension. - SSRIs/SNRIs: increased chance of serotonin syndrome. - Ergot derivatives: additive vasoconstriction. - Other triptans: cumulative vasoconstrictive effect. - CYP1A2 inhibitors: may raise naratriptan plasma levels.

Moderate Interactions (Monitor Closely): - Antihypertensives: possible blood pressure changes. - CYP3A4 inhibitors: modest increase in exposure. - Oral contraceptives: may alter hormonal balance. - Antihistamines: additive sedation. - NSAIDs: monitor for gastrointestinal irritation.